Titre : Pneumonie à pneumocoques

Pneumonie à pneumocoques : Questions médicales fréquentes

{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Pneumonie à pneumocoques : Questions médicales les plus fréquentes", "headline": "Pneumonie à pneumocoques : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Pneumonie à pneumocoques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-22", "dateModified": "2025-04-16", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Pneumonie à pneumocoques" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Pneumopathie bactérienne", "url": "https://questionsmedicales.fr/mesh/D018410", "about": { "@type": "MedicalCondition", "name": "Pneumopathie bactérienne", "code": { "@type": "MedicalCode", "code": "D018410", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C08.730.610.540" } } }, "about": { "@type": "MedicalCondition", "name": "Pneumonie à pneumocoques", "alternateName": "Pneumonia, Pneumococcal", "code": { "@type": "MedicalCode", "code": "D011018", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Antoni Torres", "url": "https://questionsmedicales.fr/author/Antoni%20Torres", "affiliation": { "@type": "Organization", "name": "Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain." } }, { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Xiaohui Fang", "url": "https://questionsmedicales.fr/author/Xiaohui%20Fang", "affiliation": { "@type": "Organization", "name": "University of California, San Francisco." } }, { "@type": "Person", "name": "Jeffrey E Gotts", "url": "https://questionsmedicales.fr/author/Jeffrey%20E%20Gotts", "affiliation": { "@type": "Organization", "name": "University of California, San Francisco." } }, { "@type": "Person", "name": "Carolyn S Calfee", "url": "https://questionsmedicales.fr/author/Carolyn%20S%20Calfee", "affiliation": { "@type": "Organization", "name": "University of California, San Francisco." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Barriers and facilitators to vaccination uptake against COVID-19, influenza, and pneumococcal pneumonia in immunosuppressed adults with immune-mediated inflammatory diseases: A qualitative interview study during the COVID-19 pandemic.", "datePublished": "2022-09-09", "url": "https://questionsmedicales.fr/article/36084032", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0267769" } }, { "@type": "ScholarlyArticle", "name": "A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult.", "datePublished": "2023-06-29", "url": "https://questionsmedicales.fr/article/37457251", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpubh.2023.1071117" } }, { "@type": "ScholarlyArticle", "name": "Effectiveness of influenza and pneumococcal vaccines on chronic obstructive pulmonary disease exacerbations.", "datePublished": "2022-06-15", "url": "https://questionsmedicales.fr/article/35705329", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/resp.14309" } }, { "@type": "ScholarlyArticle", "name": "Comparison between the STANDARD™ F S. Pneumoniae Ag FIA and BinaxNOW S. Pneumoniae Antigen Card for Detection of Streptococcus Pneumoniae Urinary Antigen.", "datePublished": "2022-05-15", "url": "https://questionsmedicales.fr/article/35780748", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.diagmicrobio.2022.115725" } }, { "@type": "ScholarlyArticle", "name": "Clinical and economic burden of pneumococcal disease among adults in Sweden: A population-based register study.", "datePublished": "2023-07-07", "url": "https://questionsmedicales.fr/article/37418396", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0287581" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies de l'appareil respiratoire", "item": "https://questionsmedicales.fr/mesh/D012140" }, { "@type": "ListItem", "position": 3, "name": "Infections de l'appareil respiratoire", "item": "https://questionsmedicales.fr/mesh/D012141" }, { "@type": "ListItem", "position": 4, "name": "Pneumopathie infectieuse", "item": "https://questionsmedicales.fr/mesh/D011014" }, { "@type": "ListItem", "position": 5, "name": "Pneumopathie bactérienne", "item": "https://questionsmedicales.fr/mesh/D018410" }, { "@type": "ListItem", "position": 6, "name": "Pneumonie à pneumocoques", "item": "https://questionsmedicales.fr/mesh/D011018" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Pneumonie à pneumocoques - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Pneumonie à pneumocoques", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-01", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Pneumonie à pneumocoques", "description": "Comment diagnostiquer une pneumonie à pneumocoques ?\nQuels tests sont utilisés pour confirmer la pneumonie ?\nQuels signes cliniques indiquent une pneumonie à pneumocoques ?\nLa culture de crachats est-elle nécessaire ?\nLes tests sanguins sont-ils utiles ?", "url": "https://questionsmedicales.fr/mesh/D011018?page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Pneumonie à pneumocoques", "description": "Quels sont les symptômes courants de la pneumonie à pneumocoques ?\nLa toux est-elle toujours productive ?\nY a-t-il des symptômes atypiques ?\nComment la douleur thoracique se manifeste-t-elle ?\nLes symptômes varient-ils selon l'âge ?", "url": "https://questionsmedicales.fr/mesh/D011018?page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Pneumonie à pneumocoques", "description": "Comment prévenir la pneumonie à pneumocoques ?\nQui devrait se faire vacciner ?\nY a-t-il d'autres mesures préventives ?\nLa vaccination est-elle efficace ?\nÀ quelle fréquence faut-il se faire vacciner ?", "url": "https://questionsmedicales.fr/mesh/D011018?page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Pneumonie à pneumocoques", "description": "Quels antibiotiques sont utilisés pour traiter cette pneumonie ?\nLe traitement nécessite-t-il une hospitalisation ?\nDes traitements symptomatiques sont-ils recommandés ?\nCombien de temps dure le traitement antibiotique ?\nDes soins de soutien sont-ils nécessaires ?", "url": "https://questionsmedicales.fr/mesh/D011018?page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Pneumonie à pneumocoques", "description": "Quelles sont les complications possibles de la pneumonie à pneumocoques ?\nComment l'empyème se développe-t-il ?\nLa pneumonie peut-elle entraîner des problèmes respiratoires chroniques ?\nQuels sont les signes d'une septicémie ?\nLes complications sont-elles plus fréquentes chez certains patients ?", "url": "https://questionsmedicales.fr/mesh/D011018?page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Pneumonie à pneumocoques", "description": "Quels sont les principaux facteurs de risque de pneumonie à pneumocoques ?\nLe tabagisme augmente-t-il le risque ?\nLes maladies pulmonaires chroniques sont-elles un facteur de risque ?\nLes enfants sont-ils à risque ?\nL'immunodépression influence-t-elle le risque ?", "url": "https://questionsmedicales.fr/mesh/D011018?page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une pneumonie à pneumocoques ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen clinique, les radiographies thoraciques et les cultures de crachats." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour confirmer la pneumonie ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent la radiographie, la tomodensitométrie et les analyses sanguines." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent une pneumonie à pneumocoques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, toux productive, douleur thoracique et difficultés respiratoires sont des signes clés." } }, { "@type": "Question", "name": "La culture de crachats est-elle nécessaire ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Elle est recommandée pour identifier le pathogène et guider le traitement antibiotique." } }, { "@type": "Question", "name": "Les tests sanguins sont-ils utiles ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent montrer des signes d'infection et aider à évaluer la gravité." } }, { "@type": "Question", "name": "Quels sont les symptômes courants de la pneumonie à pneumocoques ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, frissons, toux, douleur thoracique et essoufflement sont fréquents." } }, { "@type": "Question", "name": "La toux est-elle toujours productive ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Pas toujours, mais elle est souvent accompagnée de mucus purulent dans ce cas." } }, { "@type": "Question", "name": "Y a-t-il des symptômes atypiques ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme la confusion ou la fatigue peuvent survenir, surtout chez les personnes âgées." } }, { "@type": "Question", "name": "Comment la douleur thoracique se manifeste-t-elle ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Elle est souvent aiguë et peut s'aggraver lors de la respiration ou de la toux." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes enfants et les personnes âgées peuvent présenter des symptômes moins typiques." } }, { "@type": "Question", "name": "Comment prévenir la pneumonie à pneumocoques ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La vaccination est la méthode la plus efficace pour prévenir cette infection." } }, { "@type": "Question", "name": "Qui devrait se faire vacciner ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les enfants, les personnes âgées et celles avec des maladies chroniques doivent être vaccinés." } }, { "@type": "Question", "name": "Y a-t-il d'autres mesures préventives ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Éviter le tabagisme et maintenir une bonne hygiène respiratoire sont également importants." } }, { "@type": "Question", "name": "La vaccination est-elle efficace ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle réduit significativement le risque de pneumonie à pneumocoques et ses complications." } }, { "@type": "Question", "name": "À quelle fréquence faut-il se faire vacciner ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "La vaccination peut être répétée tous les 5 à 10 ans selon le type de vaccin et l'âge." } }, { "@type": "Question", "name": "Quels antibiotiques sont utilisés pour traiter cette pneumonie ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les pénicillines et les céphalosporines sont couramment prescrites pour traiter l'infection." } }, { "@type": "Question", "name": "Le traitement nécessite-t-il une hospitalisation ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Cela dépend de la gravité des symptômes et de l'état général du patient." } }, { "@type": "Question", "name": "Des traitements symptomatiques sont-ils recommandés ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antipyrétiques et des analgésiques peuvent aider à soulager la fièvre et la douleur." } }, { "@type": "Question", "name": "Combien de temps dure le traitement antibiotique ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "En général, le traitement dure de 5 à 10 jours, selon la réponse clinique." } }, { "@type": "Question", "name": "Des soins de soutien sont-ils nécessaires ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'hydratation et le repos sont essentiels pour favoriser la guérison." } }, { "@type": "Question", "name": "Quelles sont les complications possibles de la pneumonie à pneumocoques ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'empyème, l'abcès pulmonaire et la septicémie." } }, { "@type": "Question", "name": "Comment l'empyème se développe-t-il ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "L'empyème se produit lorsque du pus s'accumule dans la cavité pleurale à cause de l'infection." } }, { "@type": "Question", "name": "La pneumonie peut-elle entraîner des problèmes respiratoires chroniques ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des lésions pulmonaires peuvent entraîner des problèmes respiratoires à long terme." } }, { "@type": "Question", "name": "Quels sont les signes d'une septicémie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre élevée, confusion, rythme cardiaque rapide et hypotension sont des signes d'alerte." } }, { "@type": "Question", "name": "Les complications sont-elles plus fréquentes chez certains patients ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées et celles avec des comorbidités sont plus à risque de complications." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque de pneumonie à pneumocoques ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge avancé, le tabagisme, et les maladies chroniques comme le diabète." } }, { "@type": "Question", "name": "Le tabagisme augmente-t-il le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme endommage les voies respiratoires et augmente le risque d'infections." } }, { "@type": "Question", "name": "Les maladies pulmonaires chroniques sont-elles un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des conditions comme la BPCO augmentent la susceptibilité à la pneumonie." } }, { "@type": "Question", "name": "Les enfants sont-ils à risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes enfants, surtout ceux non vaccinés, sont particulièrement vulnérables." } }, { "@type": "Question", "name": "L'immunodépression influence-t-elle le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes immunodéprimées ont un risque accru de développer des infections pneumococciques." } } ] } ] }

Sources (6668 au total)

Barriers and facilitators to vaccination uptake against COVID-19, influenza, and pneumococcal pneumonia in immunosuppressed adults with immune-mediated inflammatory diseases: A qualitative interview study during the COVID-19 pandemic.

To explore barriers and facilitators to COVID-19, influenza, and pneumococcal vaccine uptake in immunosuppressed adults with immune-mediated inflammatory diseases (IMIDs).... Recruiting through national patient charities and a local hospital, participants were invited to take part in an in-depth, one-to-one, semi-structured interview with a trained qualitative researcher b... Twenty participants (75% female, 20% non-white) were recruited. Barriers and facilitators spanned contextual, individual/group and vaccine/vaccination-specific factors. Key facilitators to all vaccine... Numerous barriers and facilitators to vaccination, varying by vaccine-type, exist for immunosuppressed-IMID patients. Addressing vaccine benefits and safety for IMID-patients in clinical practice, dir...

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult.

This study aims to assess the economic impact of introducing the 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) to Thai older adult aged ≥ ... A Markov model was adopted to simulate the natural history and economic outcomes of invasive pneumococcal diseases using updated published sources and Thai databases. We reported analyses as increment... The base-case analysis of all interventions (no vaccinations [current standard of care in Thailand], PPSV23, and PCV13) showed that PPSV23 was extendedly dominated by PCV13. Among healthy individuals ... In the context of Thailand, PCV13 is recommended as the best buy and should be primarily prioritized when both costs and benefits are considered. Also, this model will be beneficial to the two-next ge...

Effectiveness of influenza and pneumococcal vaccines on chronic obstructive pulmonary disease exacerbations.

Single-study evidence of separate and combined effectiveness of influenza and pneumococcal vaccination in patients with chronic obstructive pulmonary disease (COPD) is limited. To fill this gap, we st... Our study used a self-controlled, before-and-after cohort design to assess the effectiveness of TIV and PPSV23 in COPD patients. Patients were recruited from hospitals in Tangshan City, Hebei Province... We recruited 474 COPD patients, of whom 109 received TIV, 69 received PPSV23 and 296 received TIV and PPSV23. Overall effectiveness for preventing AECOPD, pneumonia and related hospitalization were re... Influenza vaccination and PPSV23 vaccination, separately and together, can effectively reduce the risk of AECOPD, pneumonia and related hospitalization. Effectiveness for preventing AECOPD was the gre...

Comparison between the STANDARD™ F S. Pneumoniae Ag FIA and BinaxNOW S. Pneumoniae Antigen Card for Detection of Streptococcus Pneumoniae Urinary Antigen.

We compared the performance of STANDARD F S. pneumoniae Ag FIA with that of BinaxNOW S. pneumoniae Antigen Card using 206 urine samples. The performance of STANDARD F was highly comparable to that of ...

Surveillance of pneumococcal serotypes in adults hospitalised with acute lower respiratory tract infection in Bristol, UK.

Pneumococcus remains a major cause of adult lower respiratory tract infections (LRTI). Few data exist on the relative contribution of serotypes included in pneumococcal vaccines to community-acquired ... A prospective cohort study at two Bristol hospitals (UK) including all adults age ≥ 18-years hospitalised with acute lower respiratory tract disease (aLRTD) from Nov2021-Nov2022. LRTI patients were cl... Of 12,083 aLRTD admissions, 10,026 had LRTI and 2,445 provided urine: 1,097 CAP + RAD+; 207 CAP + RAD-; and 1,141 NP-LRTI. Median age was 71.1y (IQR57.9-80.2) and Charlson comorbidity index = 4 (IQR2-... Among adults hospitalised with respiratory infection, pneumococcus is an important pathogen across all subgroups, including CAP+/RAD- and NP-LRTI. Despite 20-years of PPV23 use in adults ≥ 65-years an...

Healthcare resource utilisation and cost of pneumococcal disease from 2003 to 2019 in children ≤17 years in England.

To estimate healthcare resource utilisation (HCRU) and costs associated with pneumococcal disease (PD) in children aged ≤17 years in England from 2003-2019.... A retrospective study in children aged ≤17 years was conducted using the Clinical Practice Research Datalink Gold primary care database and Hospital Episodes Statistics Admitted Patient Care database ... 1,500,686 children were followed from 2003-2019. The highest average inpatient cost per episode [£34,255 (95%CI 27,222-41,288)] was in IPD, followed by ACP [£3,549 (95%CI 3,405-3,693)] and PP [£1,498 ... From 2003-2019, primary care HCRU and costs decreased (except for PP cost), but no trends in inpatient HCRU and costs were observed. The economic burden of pneumonia, IPD and AOM remains substantial i...

Pneumococcal bacteraemia in adults over a 10-year period (2011-2020): a clinical and serotype analysis.

Streptococcus pneumoniae (pneumococcus) is a human nasopharyngeal tract coloniser responsible for invasive pneumococcal disease, which is largely vaccine preventable. Vaccination is recommended from b... To describe the clinical and serotype analysis of pneumococcus bacteraemia over a 10-year period.... A 10-year (February 2011-December 2020) retrospective review was performed on all adult (age ≥18 years) pneumococcus bacteraemia presenting to the four public hospitals in Western Sydney, Australia. C... Three hundred unique episodes of S. pneumoniae bloodstream infection (SPBI) were identified during the study period. The median age for SPBI was 63 years with 31.7% aged 70 years or older. A 94.7% had... Most patients with pneumococcal bacteraemia had age- or comorbidity-related risk factors but were not vaccinated. Two-thirds of cases occurred in people aged <70 years. 13vPCV and 23vPPV covered 41.7%...